Keyphrases
COVID-19
88%
Indonesia
62%
Meta-analysis
57%
Avian Influenza
37%
EGFR mutation
33%
COVID-19 Vaccine
29%
Systematic Meta-analysis
29%
Antibody Response
27%
Healthcare Workers
27%
Virus
25%
Whole-cell Vaccine
22%
Mortality Risk
21%
Cytological Samples
21%
Mycobacterium Tuberculosis (M. tb)
20%
COVID-19 Patients
19%
Indonesian
19%
Type 1 Diabetes Mellitus (T1DM)
19%
Hypertension
18%
Non-small Cell Lung Cancer (NSCLC)
18%
Lung Adenocarcinoma
18%
Circulating Tumor DNA (ctDNA)
18%
Pulmonary Tuberculosis
18%
Network Meta-analysis
18%
Global Prevalence
18%
Community-acquired Pneumonia
18%
SARS-CoV-2 Vaccine
18%
Co-infection
18%
Hospitalized Adults
18%
Heligmosomoides Polygyrus
18%
Severe Coronavirus Disease 2019
18%
Vaccination
17%
Surabaya
17%
Influenza Virus
16%
Mortality Rate
16%
Lung
16%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
16%
Immune Response
15%
Influenza A/H5N1 Virus
15%
Lung Tissue
15%
H5N1 Virus
15%
A(H5N1)
15%
Epidermal Growth Factor Receptor
14%
East Java Indonesia
14%
PubMed
13%
COVID-19 Vaccination
13%
Comorbidity
13%
Highly Pathogenic Avian Influenza Viruses (HPAIV)
13%
Oncology
12%
Blood Urea Nitrogen
12%
Gefitinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Coronavirinae
87%
Infection
44%
Prevalence
39%
COVID-19 Vaccine
39%
SARS Coronavirus
32%
Epidermal Growth Factor Receptor
32%
Mortality Rate
20%
Diabetes Mellitus
20%
Messenger RNA
20%
Comorbidity
18%
Lung Adenocarcinoma
18%
Lung Tuberculosis
18%
Non Small Cell Lung Cancer
18%
Community Acquired Pneumonia
18%
Avian Influenza (H5N1)
15%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Randomized Controlled Trial
14%
Influenza A Virus (H5N1)
13%
Neoplasm
13%
Virus Vaccine
12%
Vaccination
12%
Cohort Study
12%
Highly Pathogenic Avian Influenza
12%
Gefitinib
12%
Erlotinib
12%
Adverse Event
11%
Inactivated Virus Vaccine
11%
Creatinine
11%
Ureaplasma
11%
Asymptomatic Infection
10%
Retrospective Study
9%
Virus Infection
9%
Interstitial Lung Disease
9%
Circulating Tumor DNA
9%
mRNA Vaccine
9%
Systemic Sclerosis
9%
Avian Influenza
9%
Lung Disease
9%
Adenocarcinoma
9%
Serine Proteinase
9%
Acute Lung Injury
9%
Liver Injury
9%
Lung Cancer
9%
Bird
9%
Myocarditis
9%
Tuberculostatic Agent
9%
Lung Injury
9%
Infectious Agent
9%
Pneumonia
9%
Medicine and Dentistry
COVID-19
73%
Meta-Analysis
38%
Epidermal Growth Factor Receptor
35%
Infection
31%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
COVID-19 Vaccine
30%
Prevalence
28%
Systematic Review
27%
Lung
25%
Antibody Response
18%
Heligmosomoides polygyrus
18%
Mixed Infection
18%
COVID-19 Vaccination
15%
Randomized Controlled Trial
14%
Comorbidity
14%
Pleura Effusion
13%
Health Care
13%
Immune Response
12%
Exon
12%
Antibiotic Therapy
11%
Tuberculosis
10%
Mycobacterium Tuberculosis
10%
Macrophage Polarization
10%
Blood Plasma
10%
Virus Vaccine
10%
Macrophage
10%
Nematoda
10%
Vital Sign
9%
Community-Acquired Pneumonia
9%
Remote Sensing
9%
Retrospective Cohort Study
9%
Hemoptysis
9%
Liquid Biopsy
9%
Aspergilloma
9%
Malignant Pleural Effusion
9%
Bacillary Dysentery
9%
Lung Cancer
9%
Respiratory Medicine
9%
Booster Dose
9%
Oncology
9%
Liver Injury
9%
Non-Small Cell Lung Cancer
9%
Avian Influenza (H5N1)
9%
Lung Injury
9%
Highly Pathogenic Avian Influenza
9%
Adverse Event
9%
mRNA Vaccine
9%
Empyema
9%
Vasculotropin A
9%
Mesenchymal Stem Cell
9%